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Editor: Michael BreakspearStructural MRI is widely used for investigating brain atrophy in many neurodegenerative disorders, with several
research groups developing and publishing techniques to provide quantitative assessments of this longitudinal
change. Often techniques are compared through computation of required sample size estimates for future clinical
trials. However interpretation of such comparisons is rendered complex because, despite using the same publicly
available cohorts, the various techniques have been assessed with different data exclusions and different statis-
tical analysis models. We created the MIRIAD atrophy challenge in order to test various capabilities of atrophy
measurement techniques. The data consisted of 69 subjects (46 Alzheimer's disease, 23 control) who were
scanned multiple (up to twelve) times at nine visits over a follow-up period of one to two years, resulting in
708 total image sets. Nine participating groups from6 countries completed the challenge by providing volumetric
measurements of key structures (whole brain, lateral ventricle, left and right hippocampi) for each dataset and
atrophymeasurements of these structures for each time point pair (both forward and backward) of a given sub-
ject. From these results, we formally compared techniques using exactly the same dataset. First, we assessed the
repeatability of each technique using rates obtained from short intervalswhere nomeasurable atrophy is expect-
ed. For thosemeasures that provided direct measures of atrophy between pairs of images, we also assessed sym-
metry and transitivity. Then, we performed a statistical analysis in a consistent manner using linear mixed effect
models. Themodels, one for repeatedmeasures of volumemade atmultiple time-points and a second for repeat-
ed “direct” measures of change in brain volume, appropriately allowed for the correlation between measures
made on the same subject and were shown to ﬁt the data well. From these models, we obtained estimates of
the distribution of atrophy rates in the Alzheimer's disease (AD) and control groups and of required sampleBox 16, The National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK.
. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
150 D.M. Cash et al. / NeuroImage 123 (2015) 149–164sizes to detect a 25% treatment effect, in relation to healthy ageing, with 95% signiﬁcance and 80% power over
follow-up periods of 6, 12, and 24 months. Uncertainty in these estimates, and head-to-head comparisons be-
tween techniques, were carried out using the bootstrap. The lateral ventricles provided themost stable measure-
ments, followed by the brain. The hippocampi had much more variability across participants, likely because of
differences in segmentation protocol and less distinct boundaries. Most methods showed no indication of bias
based on the short-term interval results, and direct measures provided good consistency in terms of symmetry
and transitivity. The resulting annualized rates of change derived from the model ranged from, for whole
brain:−1.4% to−2.2% (AD) and−0.35% to−0.67% (control), for ventricles: 4.6% to 10.2% (AD) and 1.2% to
3.4% (control), and for hippocampi: −1.5% to −7.0% (AD) and −0.4% to −1.4% (control). There were large
and statistically signiﬁcant differences in the sample size requirements between many of the techniques. The
lowest sample sizes for each of these structures, for a trial with a 12 month follow-up period, were 242 (95%
CI: 154 to 422) for whole brain, 168 (95% CI: 112 to 282) for ventricles, 190 (95% CI: 146 to 268) for left hippo-
campi, and 158 (95% CI: 116 to 228) for right hippocampi. This analysis represents one of themost extensive sta-
tistical comparisons of a large number of different atrophymeasurement techniques from around the globe. The
challenge data will remain online and publicly available so that other groups can assess their methods.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).3 http://www.ucl.ac.uk/drc/research/miriad-scan-database.Introduction
Alzheimer's disease (AD)presents signiﬁcant challenges tohealth care
systems throughout the world as the elderly population worldwide in-
creases and no disease-modifying treatments are currently available. Ac-
curate and robust measurements are needed to aid in diagnosis, to track
disease progression, and to determine whether the underlying disease is
being modiﬁed by a potential new therapy. Whilst the primary outcome
measures for randomized controlled clinical trials of potential disease-
modifying agents are likely to be cognitive outcomes, they often suffer
from such issues as ﬂoor/ceiling effects, practice effects, and rater subjec-
tivity that results in high variability (Black et al., 2009). It is also clear that
there is a long (N10 years) prodromal period of the disease, where cogni-
tive deﬁcits areminimal and subtle, but there are numerous changes that
are observable through imaging techniques.
Rates of atrophy calculated from serial magnetic resonance imaging
(MRI) are one of themostwidely used imaging biomarkers in dementia
and are increasingly considered as potential surrogates for disease ac-
tivity, the treatment effect being the difference in the mean slopes be-
tween treated and placebo groups (Benzinger et al., 2013; Schott
et al., 2010; Villemagne et al., 2013). These measurements are often
more sensitive than cognitive measures, as illustrated by lower sample
sizes of subjects per arm thatwould be required in order to be appropri-
ately statistically powered (Jack et al., 2004). Compared to other imag-
ing biomarkers e.g., positron emission tomography (PET) measures of
amyloid deposition and hypometabolism, MRI based measures of atro-
phy are thought to provide better surrogates of disease progression,
with changes beginning before, but very close to, clinical disease onset
(Jack et al., 2013). Numerous techniques exist to compute atrophy
from longitudinal MRI scans of the brain, including (Freeborough and
Fox, 1997; Holland and Dale, 2011; Hua et al., 2013; Reuter et al.,
2012). Many of these methods have been applied to the same set of
large, publicly available cohorts, and in some cases, comparisons be-
tween differentmethods have been performed, primarily by comparing
the effect sizes of each method through the estimation of sample sizes
needed to statistically power a hypothetical clinical trial.
For the most part, direct comparisons between multiple techniques
using exactly the same dataset have not yet been performed, and such
comparisons have rarely been carried out in a blinded fashion. Another
major issue inherent to longitudinal studies of atrophy is the lack of
ground truth. In an attempt to address this, Fox et al. (2011) proposed
desirable characteristics that atrophy measurement techniques should
exhibit, including: symmetry, transitivity, comparisons with results
from manual measurements, comparison with more established tech-
niques (Schott et al., 2006), and reproducibility of measurements over
short time intervals. For these purposes,we created theMIRIAD atrophychallenge, where we provided a common dataset of serial MRI data that
could be used for a comparison of atrophy measurement techniques.
We chose the Minimal Interval Resonance Imaging in Alzheimer's Dis-
ease (MIRIAD) dataset (Malone et al., 2013) consisting of 708 T1-
volumetric scans acquired from 46 patients with a clinical diagnosis of
AD and 23 controls scanned on multiple occasions over a variety of dif-
ferent intervals on the same 1.5 T scanner, and by the same radiogra-
pher; these data have since been made an open-access resource.3
Particular features of this dataset include the availability of short-
interval follow­up scans, 2 and 6 weeks from the initial baseline scan,
allowing for thorough investigation into repeatability of atrophy mea-
surements; and a means of assessing within-day reproducibility as
most subjects had 2 viable back‐to‐back scans at 3 of the time points.
In previous studies, these scans have been used to perform atrophy sim-
ulationmodelling (Camara et al., 2008) and to estimate sample sizes for
clinical trials using both manual and automated techniques (reviewed
in Malone et al., 2013), but aside from one paper comparing results be-
tween BSI and SIENA (Smith et al., 2007), little work has been done
using this dataset to directly compare different techniques.
In designing the MIRIAD atrophy challenge we decided that an im-
portant component for comparing the different techniques of atrophy
measurement would be the required sample sizes for clinical trials.
The rationale for this choice is that given that other aspects of the design
are ﬁxed and the different methods provide reliable and repeatable
measures across the cohort, there is clear utility in using methodology
for measuring the outcome variable that requires the smallest sample
size to provide 80% (sometimes 90%) statistical power to demonstrate
a statistically signiﬁcant treatment effect if the treatment under consid-
eration truly has a clinically important disease-modifying effect (i.e.,
slowing the rate of atrophy compared to placebo). Numerous other fac-
tors can affect sample size, including the choice of outcome variable, the
length of the trial, the number of interim visits, the anticipated number
and pattern of dropouts and themethod of statistical analysis. However,
in this challenge these factors have been applied consistently across
groups, so that the primary effect on sample size is the atrophy mea-
surement technique itself.
In this paper, we describe the results from theMIRIAD atrophy chal-
lenge. From the submissions received from challenge participants, we
obtainedmeasures of short-term repeatability, symmetry, and transitiv-
ity (Fox et al., 2011), aswell as estimates of the rates of atrophy for both
AD and control groups in order to calculate required sample sizes for hy-
pothetical clinical trials. These sample size estimates provide head-to-
head comparisons of the effectiveness of these techniques.
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Data
Full details about the MIRIAD dataset, including how to obtain the
data, can be found in Malone et al. (2013). In brief, the dataset consists
of scans from 46 patients fulﬁlling National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer's Disease and Related
Disorders Association (NINCDS-ADRDA) working group criteria
(McKhann et al., 1984) for probable AD and 23 age-matched, healthy el-
derly controls scannedmultiple times over a follow-up period of up to 2
years, with subjects being scanned twice in one session at some visits.
The basic demographics of the MIRIAD subjects can be found in
Table 1. All scanning was done on a single 1.5-T scanner (GE Signa, GE
Medical Systems, Milwaukee, Wisconsin) from 2000 to 2003. Volumet-
ric T1-weighted images were acquired with an IR-FSPGR (inversion re-
covery prepared fast spoiled gradient recalled) sequence, ﬁeld of view
24 cm, 256 × 256 matrix, 124 1.5 mm slices in coronal orientation, TR
15 ms, TE 5.4 ms, ﬂip angle 15°, and TI 650 ms.MIRIAD atrophy challenge
TheMIRIAD atrophy challengewas announced as part of theMICCAI
2012 Workshop on Novel Imaging Biomarkers in Alzheimer's Disease
(NIBAD12) (Wang et al., 2012). Participants requested a login and
then downloaded data from a dedicated XNAT (eXtensible Neuroimag-
ingArchive Toolkit) (Marcus et al., 2007) server, which contained all the
image data in NIFTI (Neuroimaging Informatics Technology Initiative)
format. For each subject, only one of the baseline scans, henceforth re-
ferred to as the identiﬁed baseline, was identiﬁed to the participants.
The rest of the temporal ordering was blinded to the participants. This
blinding was performed to ensure that no added optimization could
be performed when doing change measures on back-to-back or short
interval scans. Participants submitted volumetric measures for every
dataset in the challenge, as well as change measurements between
each timepoint combination, both in the “forward” direction (e.g., base-
line to 12 months) as well as in the “backward” direction (e.g., 12
months to baseline), so that symmetry could be tested. Volume and
change measures were requested for the whole brain, ventricle, and
both left and right hippocampi. The organizers checked the received
data ﬁles with the participants to ensure that there were no problems
during transfer and then unblinded the time point ordering for statisti-
cal analysis. The initial results of the MIRIAD atrophy challenge were
presented in oral form as part of the NIBAD workshop. After the work-
shop, participants were allowed to submit outlier images that were
not of suitable quality for their analysis methods. The organizers deter-
mined consensus outliers based on the feedback from all participants
and image quality checks performed during the original data collection
process. A consensus set of nine images from seven subjects (190_F,
217_G, 235_B, 237_E, 240_C, 255_A, 255_H, 256_A, 256_C), correspond-
ing to 128 pair-wise measurements, was marked for removal from the
analysis. All participants, whilst still blinded to timepoint and disease
status, were given the option to re-run their analysis with the outliers
excluded.
A total of nine groups participated in the challenge. Several groups
submitted more than one method. Some groups only reported results
on a subset of structures, and one group provided measurements only
in terms of percentage change. An overview of each pipeline isTable 1
Demographics of MIRIAD subjects.
Group n Age Gender Baseline MMSE
Control 23 69.7 ± 7.2 52%M/48%F 29.4 ± 0.8
AD 46 69.4 ± 7.1 41%M/59%F 19.2 ± 4presented in Table 2 and detailed results can be found in both the pro-
ceedings (Wang et al., 2012) and the Supplementary material.
Reliability measurements
Wemeasured three key aspects of atrophymeasurement techniques
as deﬁned by Fox et al. (2011) that focus on plausibility and consistency.
For all analyses, the data was grouped according to disease (healthy
control and AD) in order to determine whether the behaviour of these
measurements was different based on the population.
First, volumes of brain, lateral ventricles, left and right hippocampi
from the identiﬁed baseline scanswere compared between the two dis-
ease groups. The next assessmentwas tomeasure change over short in-
terval scans. Speciﬁcally, the mean atrophy between the identiﬁed
baseline and the other baseline scan, where available, was calculated.
Two-tailed t-tests were performed on the null hypothesis that the
mean change was zero. A similar analysis was performed using the
identiﬁed baseline scan and the two-week scan. Whilst the variability
at two weeks should be larger, the change would still be expected to
be near zero. All measures of short interval change were standardized
by the volume of the structure at the identiﬁed baseline scan, using
the following formula for data when volumetric measurements were
used:
cindirect ¼ 100  ln
Vr
Vb
ð1Þ
where Vb is the volumemeasure at the identiﬁed baseline scan, and Vr is
the volumemeasure at the repeat scan. For methods where direct mea-
sures of change were available, the change was measured as:
cdirect ¼ 100  ln
Vb þ ΔV b; rð Þ
Vb
ð2Þ
where ΔV(b,r) is the (forward) measure of direct change between the
baseline and repeat scan. In the case of the INRIA group, where percent-
age change was the quantity provided, the formula used was cdirect =
100 ∗ ln(1 + ΔV(b,r) / 100). All of the values were log (ln) transformed,
as this gives a scale that approximates a percent change but is multipli-
catively symmetric.
The ﬁnal two measurements investigated the longitudinal consis-
tency of the methods regarding symmetry and transitivity. These mea-
sures were only obtained for methods doing direct measures of
atrophy since indirect measures are based purely on subtraction and
thus are inherently symmetric and transitive. Two of the directmethods
enforced symmetry in the algorithms: UCL-BSI by averaging the for-
ward and (negative) backward atrophy measurements to obtain ﬁnal
values for both directions and INRIA by the symmetry of their registra-
tion algorithm. The symmetry difference, dsym, was calculated by
looking at the ratio of the difference between the two measurements,
and the average measurement of changes:
dsym ¼ 100  ΔV b; r12ð Þ−ΔV r12; bð Þ0:5 ΔV b; r12ð Þ þ ΔV r12; bð Þð Þ ð3Þ
where ΔV(b,r12) is the forward direct measure of volume change from
the identiﬁed baseline to the repeat scan at month 12, and ΔV(r12,b) is
the negative of the backward direct measure of volume change (which
will itself usually be negative since brain volume is typically lost over
time) from the repeat month 12 to the identiﬁed baseline. For transitiv-
ity, the difference was measured as
dtrans ¼ 100  ΔV b; r12ð Þ− ΔV b; r6ð Þ þ ΔV r6; r12ð Þð Þ0:5 ΔV b; r12ð Þ þ ΔV b; r6ð Þ þ ΔV r6; r12ð Þð Þð Þ : ð4Þ
In some cases, where the amount of change in the actual subjectwas
quite small (most of the controls), differences very small in magnitude
Table 2
Summary of submissions in the MIRIAD atrophy challenge.
Research centre Submissions Bias correction Inter-subject
registration
Standard/groupwise
space
ROI method Longitudinal
registration
Image change
measure
Bahçeşehir
University
BAUMIP SPM5 (Ashburner
and
Friston, 2005)
SPM5 SPM5 SPM5, ALVIN (Kempton
et al.,
2011), FIRST (Patenaude
et al., 2011)
N/A N/A
Brain image
analysis
IOWA N4 (Tustison
et al., 2010)
BRAINS (Magnotta
et al.,
2002; Pierson et al.,
2011)
In-house template Tissue seg, ANN N/A N/A
CSIRO CSIRO Tissue seg (Van
Leemput et al.,
1999)
NiftyReg Within-subject Tissue seg, multi-atlas
(Hsu et al., 2002)
N/A N/A
Harvard MGH FS_ORIG, FS_BETA N3 (Sled et al.,
1998)
Robust inverse
consistent
(Reuter et al., 2010)
Within-subject
(Reuter et al., 2012)
Atlas (Dale et al., 1999;
Fischl, 2012; Fischl et al.,
2002)
N/A N/A
INRIAa INRIA N3 Demons-LCC (Lorenzi
et al.,
2013; Vercauteren
et al., 2008)
ADNI 200 HC Loose regions Demons-LCC Regional ﬂux
analysis
(Lorenzi et al.,
2015)
Mayo Clinic MAYO, MAYO_BSIc,
MAYO_TBM
N3/SPM5 NiftyReg ADNI 200 HC + 200
AD
SPM5, Seg Prop NiftyReg 9DOF
(BSI), SyN (TBM)
BSI (Gunter et al.,
2003),
Jacobian
integration (TBM)
Montreal
Neurologic
Institute
MNI ANIMAL
(Collins and
Evans, 1997)
ICBM152 Within-subject
template
Patch-based (Coupé
et al.,
2011; Eskildsen et al.,
2012;
Fonov et al., 2012)
N/A N/A
University
College
London
UCL, UCL_BSI N3 NiftyReg
(Ourselin et al.,
2001)
Challenge data and
template library
Multi-atlas Seg Prop
(Cardoso et al., 2013)
NiftyReg
(Modat et al.,
2010)
DBC, Symmetric
BSI
(Leung et al.,
2011b)
University of
Pennsylvaniab
UPENN, UPENN_DBM FLIRT (Jenkinson and
Smith, 2001) +SyN
Within-subject Multi-atlas seg propd
(Wang et al., 2012)
SyN (Avants
et al., 2008)
Mesh-based
(half-way space)
(Yushkevich et al.,
2010)
a INRIA provided submissions only for the lateral ventricles and hippocampi, b University of Pennsylvania only provided submissions for the hippocampi, c theMAYO_BSI submission only
included whole brain and lateral ventricle atrophy, and d template for multi atlas segmentation propagation in UPENN technique consisted of 30 randomly selected ADNI.
152 D.M. Cash et al. / NeuroImage 123 (2015) 149–164could result in large errors and outliers. As a result, these differences
were reported using median (with 95% conﬁdence intervals) rather
than the mean.
Statistical analysis of imaging outcome measures
A number of different statistical approaches can be used to analyse a
clinical trial with an imaging outcome, with choice between them in
part dependent upon the complexity of the design. With only a single di-
rect (Frost et al., 2004) measure of change (such as a measure of atrophy
derived from a boundary shift integral (Freeborough and Fox, 1997)) a
two-sample t-test can be used (provided normality assumptions hold
and/or the sample size is large). Another option is to measure brain vol-
umeat baseline (pre-randomization) and at the endof follow-up, produc-
ing an indirectmeasure of change as calculated by subtracting the two
volumes,with a t-test again being used to compare the treatment andpla-
cebo groups. Alternatively, the baseline can be used as a covariate in an
analysis of covariance (ANCOVA), an approach that increases statistical
power (Frison and Pocock, 1992).Withmultiple repeatedmeasures, a va-
riety of approaches are possible, with linear mixed models one option
(see Frost et al., 2008 for sample size requirements when using linear
mixed models). However, for simplicity in the analysis presented here,
we restrict attention to designs where patients are seen only once pre-,
and once post-, randomization. For designs where the outcome is an indi-
rectmeasure of change (calculated by subtraction of two volume mea-
sures) we assume that the trial will be analysed using a comparison of
changes, rather than using ANCOVA. Here we consider clinical trials of
length 6, 12 and 24 months, three intervals over which trials of disease-
modifying therapies are often considered.To carry out a sample size calculation for a particular clinical trial de-
sign with an imaging outcome, two quantities are key. First, it is neces-
sary to specify the anticipated treatment effect on the mean atrophy
rate. The current consensus is that a 25% slowing of atrophywould likely
be a clinically signiﬁcant disease modiﬁcation. Whether this 25%
slowing should be in relation to the atrophy rate seen in a healthy age-
ing population or an absolute slowing is still an ongoing discussion in
the community (Holland et al., 2012; Hua et al., 2013). Here, we adopt
the former approach.
The second key quantity is the anticipated variance of the estimated
treatment effect. For the simple trial designs considered here where the
outcome is a measure of rate of change over a single time-interval, this
variance is a simple function of the sample size and the variance of the
rate of change. This variance is expected to decrease with increasing
follow-up time, since the within-subject component will decrease
over time until the overall variance asymptotically approaches the
between-subject variance (Schott et al., 2006).With repeatedmeasures
over multiple time-points variances of changes over particular time in-
tervals can be separately empirically estimated. However this approach
can give rise to implausible behaviour through the play of chance, with
for example variances ﬁrst increasing and then decreasingwith increas-
ing follow-up. Our preferred approach and the one adopted here is to
ﬁrst identify a linear mixed model (Verbeke and Molenberghs, 2000)
that ﬁts the data well and then to use the estimated parameters from
this model to predict variances of changes over all the time intervals
of interest and hence required sample sizes for clinical trials. To do
this we make the commonly adopted assumption that variability will
be unaltered by treatment and that variability in both groups will
mimic that seen in the observational cohort of patients.
153D.M. Cash et al. / NeuroImage 123 (2015) 149–164Model for analysis of repeated measurements of brain volume
The model for repeated observations on subjects in a single group is
a random slopemodel with ﬁxed subject effects. Since theMIRIAD data
includes measures from more than one scan at some visits the model
also incorporates random visit effects.
yi jk ¼ αi þ β þ bið Þ ti j þ di j þ ei jk
with bi  N 0;σ2b
 
; di j  N 0;σ2d
 
andei j  N 0;σ2e
  ð5Þ
Here yijk is the value of the outcome variable (e.g., brain volume) for
the ith subject, attending their jth visit (j= 1 to 9) with the measure-
mentmade at the kth scan (k=1 atmost visits, but 1 or 2 at those visits
with repeat scans) and tij is the time of the jth visit (in years) relative to
the baseline visit. The β term is the ﬁxed effect representing the mean
atrophy rate per unit time, whilst bi is the subject-level random effect
that allows for variability in atrophy rate between subjects. The terms
dij and eijk together represent within-subject variability over and
above that accounted for by atrophy for the ith subject. This is
partitioned into between-visit (dij) and within-visit between-scan vari-
ability (eijk). From themodel in Eq. (5) the difference betweenmeasures
at visit j1 (scan k1) and at visit j2 (scan k2) for the ith subject is given by
the following formula.
yi j2k2−yi j1k1 ¼ β þ bið Þ ti j2 −ti j1
 
− di j1 þ di j2 − ei j1k1 þ ei j2k2 ð6Þ
Using the general results that Var(A+ B)=Var(A)+Var(B) provid-
ed that A and B are independent and that Var(cA)= c2(Var(A)) where c
is a constant, the implied variance of this difference is given by the fol-
lowing formula.
Var yi j2k2−yi j1k1
 
¼ ti j2−ti j1
 2σ2b þ 2σ2d þ 2σ2e ð7Þ
It follows that the implied variance of a rate of change derived from a
difference between two measures on the same subject is as follows.
Var yi j2k2−yi j1k1
 
= ti j2−ti j1
 h i ¼ σ2b þ 2 σ2d þ σ2e
 
= ti j2−ti j1
 2 ð8Þ
In Eq. (8) σb2 is the between-subject variance in rates of change
whilst the remainder of the variance formula represents the within-
subject variance. Provided that themodel is correct, the latter decreases
with increasing follow-up whilst the former remains constant, as men-
tioned in the Statistical Analysis of Imaging Outcome Measures.
Model for analysis of repeated “direct” measures of change in
brain volume
Here the model for repeated measures on subjects in a single group
extends that recommended by Frost et al. (2004) for repeated “direct”
measures of change. Again the basic model is extended to incorporate
random visit effects as follows.
ci j1k1 j2k2 ¼ β þ bið Þ ti j2 −ti j1
 
− ui j1 þ ui j2 − vi j1k1 þ vi j2k2 þwij1k1 j2k2
bi  N 0;σ2b
 
; ui j  N 0;σ2u
 
; vi jk  N 0;σ2v
 
; wij1k1 j2k2  N 0;σ2w
 
ð9Þ
Here ci j1k1 j2k2 is the measured change between visit j1 (scan k1) and
visit j2 (scan k2) for the ith subject. The uijs are subject-speciﬁc random
visit effects impacting on any “direct” changemeasured from, or ending
at, the jth visit. Two such visit effects impact on each scan pair, with that
for the “start” visit having a negative sign and that for the “end” visit
having a positive sign. The vijks are analogous effects relating to scans,
whilst wij1k1 j2k2 is unexplained residual variability.The model here has strong parallels with that for direct differences
(Eq. (6)). These parallels, and the rationale for these models, are
discussed in detail in Frost et al. (2004). In brief the use of direct mea-
surements is expected to reduce the variance of the visit and scan effects
(i.e., σu2 and σv2 in Eq. (9) are expected to be markedly smaller than σd2
and σe2 in Eq. (6) respectively) whilst the wij1k1 j2k2 terms in Eq. (9),
which arise because direct measures of change are not perfectly addi-
tive, are typically small in magnitude.
For the model speciﬁed in Eq. (9) the implied variance of a measure
of change is as follows.
Var ci j1k1 j2k2
  ¼ ti j2−ti j1
 2σ2b þ 2σ2u þ 2σ2v þ σ2w ð10Þ
It follows that the implied variance of a rate of change is as follows.
Var ci j1k1 j2k2
 
= ti j2−ti j1
   ¼ σ2b þ 2σ2u þ 2σ2v þ σ2w
 
= ti j2−ti j1
 2 ð11Þ
As with Eq. (8) here σb2 is the between-subject variance in rates of
change whilst the remainder of the variance formula represents the
within-subject variance, which decreases with increasing follow-up.
Required sample sizes for clinical trials
Assuming that a putative treatment can reduce the excess atrophy
rate (as discussed above, for the purposes of this study over and above
that seen in healthy controls) by 25% without altering variability, stan-
dard formulae give the following sample size requirements for a trial
with a single measure of change and equal numbers in each group, if
that trial is to have 80% statistical power to detect a treatment effect
using a conventional two-sided signiﬁcance level of 5%.
N ¼ 2 1:960þ 0:842ð Þ= 0:25 ESð Þ½ 2 ð12Þ
where ES ¼ βCase−βControlð Þ=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var rateCaseð Þ
p
ð13Þ
HereN is the required sample size per group,βCase andβControl are the
respective mean rates of change and Var(rateCase) is the relevant vari-
ance of the rate of change (Eq. (8) or Eq. (11)) in patients with
Alzheimer's disease (cases). ES is an effect size: a standardized measure
of the difference in the mean rate of atrophy between two groups. This
formula can be used for trials with a single “indirect” or “direct” mea-
sure of change for each subject. In the former case the approach ismath-
ematically equivalent to that proposed by Diggle et al. (2002).
Transformations, omitted points and other modelling considerations
Whole brain atrophy and hippocampal atrophy are typically
expressed as percentage changes and hence most appropriately
analysed after logarithmic transformation. Frost et al. (2004) provide
details of the exact methodology. Ventricular expansion rates are most
commonly analysed in absolute terms of volume change without such
a transformation or normalization to baseline volume. However, we
found that absolute rates of change in this cohort appeared to increase
with increasing follow-up, implying that a percentage change for ventri-
cle expansionwasmore appropriate. Thus, and for consistency with the
other outcomes, we utilized a logarithmic transformation for all
measures.
Conﬁdence intervals for sample sizes and head-to-head comparisons
When attempting to compare imaging techniques on the basis of
sample size estimates it is important to consider uncertainty in sample
size calculations. We did this using bootstrap resampling methodology
(Efron and Tibshirani, 1994). Speciﬁcally we constructed non-
parametric, bias-corrected and accelerated (BCa) conﬁdence intervals
154 D.M. Cash et al. / NeuroImage 123 (2015) 149–164from2000bootstrap samples for each of our sample size estimates. Each
bootstrap sample included the same number of AD cases and controls as
the original sample. The conﬁdence intervals were constructed on the
“effect size” scale, since the distribution of estimated effect sizes is likely
to be more symmetric than that of estimated sample sizes and so conﬁ-
dence intervals calculated on this scale are likely to have better coverage
properties. Bootstrap conﬁdence intervals were also calculated for the
between and within components of variance for the linear mixed
models using an analogous approach.
Head-to-head comparisons of sample size requirements between
pairs of imagingmethodologies weremade by considering the distribu-
tion of the paired differences in effect sizes estimates over the 2000
bootstrap samples. Where more than 97.5% of these comparisons
were in favour of one of the methodologies the difference was judged
statistically signiﬁcant at the 5% level (two-sided test).
For most techniques and most structures the models speciﬁed in
Eqs. (5) and (9) converged, yielding reliable parameter estimates
when ﬁtted in Stata 12. However on occasions convergence problems
were encountered either when ﬁtting the model to the full data or to
bootstrap samples drawn from the data. This occurred when one of
the components of variance was estimated to be zero or close to
zero. For six structure–technique combinations (BAUMIP for left
and right hippocampi, CSIRO for left hippocampus, INRIA for right
hippocampus, MAYO_BSI for whole brain and MNI for right hippo-
campus) such convergence problems were encountered in more
than 1% of the bootstrap resamples. For these structure–technique
combinations the relevant model in controls was replaced by oneFig. 1.Baseline volumes of eachmethod for (a)whole brain, (b) lateral ventricles, (c) left hippoc
and blue circles indicate the control group for each technique.constraining both σb2 and σd2 (Eq. (5)) or both σb2 and σu2 (Eq. (9)) to
be 0. For all but the BAUMIP-left hippocampus combination (where
convergence was not achieved in 2.35% of bootstrap samples) this
modiﬁcation to the model reduced the number of samples with con-
vergence problems to below 1%. The impact of this modiﬁcation to
the model for controls had a negligible impact on the required sample
size in each setting.
Results
The Supplemental Table shows the extent of all of the data collected
in the MIRIAD study and previously reported, highlighting the afore-
mentioned 9 scans and 128 corresponding image pairs from 7 subjects
thatwere excluded here on quality grounds. Subjectswere seen at base-
line, 2, 6, 12, 26, 38, 52, 78 and 104 weeks with repeat scans taken on
three occasions (baseline, 6 and 38 weeks). All 23 controls and 44 out
of the 46 AD cases attended the 52-week follow-up with high retention
rates at the visits in the intervening period. A subset of the subjects
returned for additional scans at 78 and 104 weeks that were not part
of the original imaging protocol. Each subject providedmeasures of “di-
rect” change for up to sixty-six (12×11/2) scan pairswith three of these
being same day scan pairs.
Fig. 1 shows the mean and 95% conﬁdence interval of the raw vol-
umemeasurements (uncorrected for overall head size) on the identiﬁed
baseline scan, separated by disease group, for all four structures and for
each technique. There was good group separation across all structures
between AD and controls (no pair of 95% conﬁdence intervalsampus and (d) right hippocampus for all groups. Red squares indicate the ADpatient group
Fig. 2. Back to back and two week repeatability measures for all four regions. All measures are provided in terms of % difference from baseline. Red squares = AD, blue circles = controls. Diamond markers represent truncation of the conﬁdence
interval if out of range.
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Table 3
Median (95% CI) symmetry differences by structure, group, and technique. These differences are between the forward and backward atrophy, divided by the averagemeasures of atrophy.
The UCL and INRIA measures are designed to be symmetric: thus there are no differences and they were excluded.
Group Brain Ventricle Left hippocampus Right hippocampus
HC AD HC AD HC AD HC AD
Mayo_BSI 0.0% (0.0, 0.0) 0.0% (−0.2, 0.0) 0.0% (0.0, 0.0) 0.0% (−0.1, 0.0) N/A N/A N/A N/A
Mayo_TBM −0.9%
(−3.7, 1.4)
−1.4%
(−2.3,−0.5)
0.0% (−1.1, 2.7) 0.0% (−0.4, 0.4) −6.0% (−11.1, 1.7) −0.3% (−2.4, 1.6) 2.3% (−4.7, 5.2) −1.2% (−3.5, 1.8)
UPenn_DBM N/A N/A N/A N/A 9.6% (−10.4, 54.4) 3.3% (−1.1, 8.0) −13.1% (−56.5, 49.2) −8.5% (−19.4, 9.9)
156 D.M. Cash et al. / NeuroImage 123 (2015) 149–164overlapped) for each technique. The ventricles were overall the most
consistently measured. The whole brain had more variability, but was
more consistent compared to the hippocampi, where there was a 2.3-
to 2.7-fold difference in volume between the techniques that had the
smallest mean hippocampal volume and those with the largest.
Fig. 2 shows the short-term repeatability measures for all four struc-
tures, with the left column representing the same day measurement
and the right column representing the two week change. Whilst most
of the methods have 95% conﬁdence intervals spanning 0, providing no
statistically signiﬁcant evidence of change, methods from three groups
did provide some evidence of bias. The Iowa group had atrophy rates
that were signiﬁcantly different from zero in the two-week repeatability
measure for all four regions for the AD group and three of the four (ven-
tricle and hippocampi) for the control group. The INRIA group had non-
zero atrophy rates for the hippocampi in all groups, both for the back to
back and twoweekmeasures. Finally, all but one of the BAUMIPmeasures
of mean short-term atrophy were signiﬁcantly different from 0.
Tables 3 and 4 provide results from the symmetry and transitivity
assessments for the direct change methods. Most methods show very
small differences in these measures, with the main exception being
the hippocampi of the controls.
Fig. 3 shows mean atrophy rates with 95% conﬁdence intervals
estimated both from single pairs of scans 12 months apart and from
all available data using our linear mixed model approach. Results are
shown for each technique and each structure, separately for AD cases
and healthy controls. Typically the differences between the techniques
are similarwhether the one-year rates or themodelled rates are consid-
ered, but conﬁdence intervals are markedly reduced when considering
results that utilize all of the data. Modelled estimates of the mean
whole brain atrophy rate in AD subjects differ according to the tech-
nique used – in some cases showing signiﬁcant differences between
techniques – from a minimum of 1.42%/year (95% CI 1.24 to 1.60%/
year) to a maximum of 2.19%/year (95% CI 1.74 to 2.63%/year). Mean
whole brain atrophy rates in controls are more homogeneous across
techniques, as are ventricular atrophy rates in both groups. In contrast
hippocampal atrophy rates, particularly in AD subjects, differ quite
markedly across techniques. Here 95% conﬁdence intervals for the
means frequently do not overlap.Table 4
Median (95% CI) transitivity differences by structure, group, and technique. Transitivity differe
coming from summing baseline and 6 months to 6 months and 12 months, and the other com
measures.
Group Brain Ventricle
HC AD HC AD
INRIA N/A N/A −1.7%
(−3.4,−0.3)
−0.8%
(−1.4, 0.1
Mayo_ BSI 0.0%
(−0.3, 1.5)
0.0%
(0.0, 0.0)
−0.2%
(−0.6, 0.6)
0.2%
(0.1, 0.4)
Mayo_ TBM 1.4%
(−2.3, 5.2)
−2.2%
(−3.6,−0.8)
0.9%
(−1.7, 2.0)
−3.5%
(−3.8,−2
UCL_ BSI 0.5%
(−0.1, 1.4)
0.2%
(−0.2, 0.4)
0.1%
(−0.2, 0.2)
0.0%
(0.0, 0.2)
UPenn_DBM N/A N/A N/A N/AFig. 4 illustrates the extent to which themodels ﬁt the data, using one
technique for each structure as exemplars. For each of the sixty three scan
pairs (sixty-six less the three same-day scan pairs) the empirical mean
rates are contrasted with those predicted by the linear mixed model.
The ﬁgures illustrate the extent to which means and standard deviations
can differwhen estimated empirically evenwhen follow-up times are the
same or similar. For each of the techniques shown,mean rates appear ap-
proximately constant, at least over time intervals of more than a few
weeks. In addition standard deviations of rates of change decrease as
follow-up increases, with the pattern of the decline well described by
the linear mixed model. In general similarly good ﬁts of the models to
the data were seen for the other techniques.
Table 5 presents the between (σb2) and within (σw2 ) components of
variance in atrophy rates for each technique and each structure in the
AD patients. These can be used to compute the total variance over any
follow-up time of t years (σb2 + σw2 /t2). The formula indicates that – as
expected, andpreviously demonstrated (Schott et al., 2006) – the longer
the follow-up the greater the importance of the between subject
variance.
Table 6 presents the required total sample sizes (both groups com-
bined) for 6, 12 and 24 month clinical trials for each structure and for
each technique. 95% bootstrap conﬁdence intervals are also shown. Re-
sults shown in bold and underlined purple text are those requiring the
smallest sample size for each structure and time interval. Those
shown in underlined and green text are not statistically signiﬁcantly
worse than those shown in purple, as assessed through pairwise com-
parison of the bootstrap sample size estimates.
For whole brain atrophy the UCL boundary shift integral approach
gives the smallest required sample sizes. For sixmonth trials the required
sample size with this technique is statistically signiﬁcantly smaller than
those for all other techniques. For two year trials the UCL technique
gives the smallest sample size, but the advantage over several of the
other techniques is not statistically signiﬁcant. This reﬂects the fact
(seen in Table 2) that the UCL technique has markedly smaller within-
subject, but not between-subject variability than the other techniques.
For ventricular expansion, there were many submissions (8 submis-
sions at 6 months, and 3 submissions at 12 and 24 months) that show
no statistically signiﬁcant evidence that they are worse than the lowestnces are deﬁned to be the difference between the two 12 month atrophy measures (one
ing from the direct baseline to 12 months), divide by the average of these two atrophy
Left hippocampus Right hippocampus
HC AD HC AD
)
1.7%
(−3.1, 8.8)
0.0%
(−1.0, 2.3)
−0.1%
(−4.2, 5.7)
−1.8%
(−2.9,−0.6)
N/A N/A N/A N/A
.2)
−3.5%
(−33.8, 23.6)
−1.5%
(−5.4, 10.2)
19.5%
(−3.8, 50.1)
−3.2%
(−11.5, 12.5)
14.9%
(−8.5, 35.4)
0.2%
(−0.8, 5.0)
0.8%
(−8.3, 17.0)
−1.3%
(−3.7, 6.1)
−4.1%
(−64.0, 50.6)
−2.8%
(−11.2, 2.9)
−1.6%
(−42.0, 64.2)
−9.8%
(−25.2, 4.9)
Fig. 3.Mean atrophy rateswith 95% conﬁdence intervals estimated (left) froma single pair of scans 12months apart and (right) fromall available data using statistical linearmixedmodels.
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Fig. 4. An illustration of the extent towhich the statisticalmodels ﬁt the data, using one technique for each structure and selected techniques as exemplars. For each of the sixty-three scan
pairs (sixty-six less the three same-day scan pairs) the empirical mean rates are contrasted with those predicted by the linear mixed model.
158 D.M. Cash et al. / NeuroImage 123 (2015) 149–164sample size achieved by the INRIA technique. INRIA's rates of ventricular
expansion, and the associated variances, aremuch lower than the rest of
the groups. It is worth noting that INRIA's deﬁnition for the region over
which ventricular expansion is computed not on a traditional anatomi-
cal basis (see Fig. 5), but rather through identifying the most sensitive
areas of contraction and expansion estimated through longitudinal
non-linear registration in an independent training set (ADNI). For this
reason, the resulting probabilistic region is determined at the same
time by the anatomical information represented in the images, and by
the underlying registration model (LCC-logDemons). In particular, the
localization of the sensitive areas of volume changes reﬂects the
smoothness assumptions of the registration algorithm. As with the
other structures considered here marked reductions in sample size are
achieved by extending follow-up from 6 to 12months, with the beneﬁt
of further extension to 24 months less marked.
For hippocampal atrophy there are very marked differences in sam-
ple sizes according to the technique used. For the right hippocampus,
required sample sizes are smallest using the INRIA technique with all
comparisons with other techniques statistically signiﬁcant. For the left
hippocampus the INRIA technique gives the smallest required sample
size over 6 months, but this is very similar to that for the Mayo tech-
nique, which becomes the most efﬁcient over longer follow-up inter-
vals. Whilst the sample sizes are the lowest, there is evidence from the
short-term repeatability measures that INRIA's hippocampal measures
has evidence for some bias in both the AD and control groups.Discussion
We have performed an extensive statistical analysis making com-
parisons amongwhat we believe to be the largest collection of different
imaging techniques ever compared head-to-head in a blinded single
analysis. The comparative analysis has been carried out using the
MIRIAD dataset, which although not the largest data-set in terms of
numbers of subjects, has the advantage of including multiple measures
of atrophy over a range of different intervals from two weeks up to two
years. This makes the MIRIAD dataset particularly useful for accurately
quantifying the between and within subject variability in rates of atro-
phy; this variability is a key component of required sample sizes for hy-
pothetical clinical trials in AD, our primary outcome measure.
All participants provided measurements for every dataset in the
challenge, allowing for a more accurate comparison between methods.
In an effort to encourage researchers to provide clearer comparisons be-
tween different methods and research studies on the most widely used
cohort in the community, the Alzheimer's Disease Neuroimaging Initia-
tive (ADNI) has created standardized analysis datasets (Wyman et al.,
2012). The fact that all techniques were assessed on exactly the same
data, with only minimal exclusion of poor quality scans is a strength
of our analysis. In other comparative studies, the number of images in-
cluded for each technique has not always been controlled. For example,
in the analysis reported by Holland et al. (2012), the number of subjects
included in the analysis ranged from 572 to 733 depending on the
Table 5
Between (σb2) and within (σw2 ) components of variance over one year (95% CI) in the AD subjects by structure and technique. These can be used to compute the total variance of rates of
change over any follow-up time of t years (σb2 + σw2 /t2).
Brain Ventricle Left hippocampus Right hippocampus
Between
subject
variance
(%/year)2
Within subject
variance
(%/year)2
Between subject
variance
(%/year)2
Within subject
variance
(%/year)2
Between subject
variance
(%/year)2
Within subject
variance
(%/year)2
Between subject
variance
(%/year)2
Within subject
variance
(%/year)2
BAUMIP[I] 1.88
(1.34, 2.67)
1.14
(0.78, 1.70)
19.21
(11.62, 34.01)
3.58
(2.72, 4.70)
0.17
(0.00, 5.83)
38.57
(10.23,152.04)
21.57
(3.56, 55.63)
48.78
(22.38, 102.40)
CSIRO[I] 0.21
(0.12, 0.35)
0.54
(0.41, 0.71)
14.88
(10.46, 22.45)
2.85
(2.17, 4.10)
3.27
(1.54, 6.61)
9.59
(6.80, 15.74)
3.03
(1.39, 6.36)
7.77
(5.99, 10.96)
FS51ORIG[I] 0.81
(0.46, 1.62)
2.53
(1.60, 5.29)
14.85
(10.30, 23.58)
3.04
(2.29, 4.12)
3.65
(1.88, 6.84)
5.56
(4.49, 7.38)
4.47
(2.48, 8.01)
7.12
(5.69, 9.33)
FS52BETA[I] – – 14.36
(9.93, 23.26)
3.00
(2.25, 4.08)
3.42
(2.12, 5.41)
6.15
(4.86, 7.94)
4.90
(2.62, 8.60)
6.55
(5.29, 8.96)
INRIA[D] – – 3.18
(2.28, 4.92)
0.82
(0.59, 1.38)
5.84
(4.39, 8.10)
1.92
(1.47, 2.79)
5.07
(3.59, 7.23)
2.30
(1.74, 3.50)
IOWA[I] 0.77
(0.46, 1.24)
1.17
(0.76, 2.43)
10.41
(6.79, 17.46)
3.84
(3.01, 5.05)
12.26
(7.00, 21.6)
19.62
(11.85, 41.32)
19.24
(13.53, 27.73)
15.90
(10.36, 24.40)
MAYO[I] 1.29
(0.90, 1.90)
0.86
(0.69, 1.11)
14.54
(10.12, 22.28)
3.57
(2.72, 5.19)
4.90
(3.09, 8.26)
4.37
(3.58, 5.40)
10.4
(6.92, 16.18)
7.78
(6.13, 10.41)
MAYO_BSI[D] 0.96
(0.53, 1.63)
1.46
(1.02, 2.09)
13.86
(9.55, 21.08)
4.31
(3.35, 6.25)
– – – –
MAYO_TBM[D] 1.01
(0.67, 1.58)
0.58
(0.46, 0.71)
12.36
(8.51, 19.51)
2.96
(2.25, 4.60)
2.19
(1.34, 3.62)
1.92
(1.55, 2.33)
2.32
(1.30, 4.22)
1.92
(1.56, 2.36)
MNI[I] 0.41
(0.21, 0.66)
0.65
(0.40, 1.15)
14.43
(9.96, 23.54)
3.12
(2.37, 4.17)
1.94
(0.85, 4.28)
5.40
(4.42, 6.58)
2.67
(1.27, 5.50)
5.54
(4.67, 6.62)
UCL[I] 0.40
(0.18, 0.76)
1.08
(0.71, 1.68)
17.17
(12.03, 26.46)
3.94
(3.02, 5.24)
4.24
(1.72, 9.73)
12.00
(9.49, 15.62)
4.60
(2.62, 7.73)
10.05
(8.24, 13.78)
UCL_BSI[D] 0.47
(0.32, 0.72)
0.19
(0.14, 0.38)
15.52
(10.91, 23.61)
2.80
(2.11, 4.31)
10.00
(6.35, 16.59)
6.93
(5.47, 9.16)
8.50
(5.08, 13.87)
7.51
(6.15, 9.46)
UPENN[I] – – – – 1.65
(0.88, 2.89)
2.53
(1.92, 3.25)
1.97
(1.10, 3.19)
1.98
(1.60, 2.71)
UPENN_DBM[D] – – – – 1.64
(0.93, 2.89)
2.61
(2.02, 3.34)
1.83
(1.04, 2.96)
2.10
(1.72, 2.75)
159D.M. Cash et al. / NeuroImage 123 (2015) 149–164method. Aswell as being consistent across techniqueswe felt that, since
our aim was to compute required sample sizes for hypothetical treat-
ment trials, the number of exclusions should be small. This is because
an important consideration in assessing the reliability of results from
any clinical trial is the extent of missing data since this has the potential
to introduce bias. For example, a study by Hua et al. (2013) illustrated
that selective data exclusion, albeit based solely on post-hoc removal
of data with implausible atrophy rates, will result in a bias towards
lower required sample sizes.
A further strength of our analysis is our use of linear mixed effect
models. The MIRIAD data has been used in a similar manner before
(Smith et al., 2007) to compare BSI, SIENA, and SIENAX. In their study,
they also obtained measures of repeatability using the same day scan
and transitivity. However, instead of using linear mixed effect models,
the comparison of atrophy rates was done by comparing t-statistics on
whole brain atrophy measures of the ﬁrst and last scans for each subject.
The incorporation of linear mixed effect models in the MIRIAD atrophy
challenge allows for estimates of the various components of variance
that determine required sample sizes. Variances could alternatively
have been separately empirically estimated for each interval. The advan-
tage of using a linear mixed model is that implausible inconsistencies
(such as variances changing non-monotonically with increasing scan in-
terval) are eliminated with variance components estimated in a statisti-
cally efﬁcient manner using all available data. The linear mixed model
used for the repeated “direct” measures of change (Frost et al., 2004) is
less simplistic than that used by others (Bernal-Rusiel et al., 2012;Holland
et al., 2012) in that it incorporates visit (and scan effects)which act in dif-
ferent directions depending upon whether a particular “direct”measure
starts from, or ends at, the visit (scan) in question. These visit and scan ef-
fects, which were statistically signiﬁcant in almost all models, should in
our opinion be routinely included in all analysismodels for repeatedmea-
sures of “direct” change.The structure that wasmost consistent across all groups was the lat-
eral ventricles, with sample sizes for a one year trial of the order of 200
to 300 for most techniques. This is likely due to the fact that the bound-
ary around this structure is clear and distinct, primarily CSF bordered by
whitematter, and the anatomical deﬁnition is consistent across centres.
A previous study (Kempton et al., 2011) validated different lateral ven-
tricle segmentation algorithms (ALVIN, FSL FIRST, FreeSurfer) using
numerous criteria, including similarity to a “gold standard” manual la-
belling, reproducibility between different sequences and scans with in-
tervals of 90 days or less, and sensitivity to longitudinal change. The
results also showed high agreement within the AD and elderly popula-
tion between all methods.Whilst changes in the ventricles are sensitive
measures of brain atrophy, as a large percentage of tissue loss is
reﬂected in ventricle expansion, it is not a very speciﬁc measure in
terms of dementia, as there can be numerous reasons for ventricle ex-
pansion and contraction besides atrophy, including hydration. Different
subtypes of dementiawill also show similar rates of ventricle expansion.
Whole brain measurements, whilst not as consistent as the lateral
ventricles, still showed a reasonable level of consistency across groups.
Required sample sizeswere typically larger than for ventricular atrophy.
The drop in consistency compared to lateral ventricles is likely due pri-
marily to partial volume effects, whichwill bemuch greater on the con-
voluted cortical surfacewhen compared to themore simple structure of
the ventricle. In validation studies on different brain segmentation algo-
rithms (Eskildsen et al., 2012; Leung et al., 2011a), voxels on the cortical
surface boundary, especially those near the temporal lobe, seemed to be
the most likely source of mis-segmentation.
In both whole brain and ventricles, resulting sample size estimates
correspond well with the sample sizes estimated from the ADNI cohort
using the same sample size formula and atrophy measurement
methods. For example, the estimated sample size for a one year study
using the UCL KN-BSI method in the brain region was 242 (152 to
Table 6
Required total sample sizes (both groups combined) for clinical trials assuming that a putative treatment can reduce the excess atrophy rate (over and above that seen in healthy controls) by 25%without altering variability. Calculations assume that the
trial will have 80% statistical power to detect a treatment effect using a conventional two-sided signiﬁcance level of 5%. Results shown in bold and underlined purple are the best for each structure and time interval. Those underlined and shown in green
are not statistically signiﬁcantly worse than best.
Brain Ventricle Left hippocampus Right hippocampus
6 months 1 year 2 years 6 months 1 year 2 years 6 months 1 year 2 years 6 months 1 year 2 years
BAUMIP[I] 1044
(626 to 1994)
490
(282 to 956)
352
(184 to 722)
452 
(276 to 1136)
308
(176 to 830)
272 
(148 to 750)
8286 
(2186 to 
128964)
2080 
(692 to 
32242)
528 
(212 to 1876)
10266 
(3848 to 109386)
3334 
(1436 to 34662)
1600 
(774 to 23760)
CSIRO[I] 1298
(818 to 2306)
412 
(260 to 688)
192 
(116 to 334)
316 
(206 to 528)
214 
(134 to 352)
188 
(116 to 316)
5928 
(2754 to 
20324)
1832 
(888 to 7184)
808 
(366 to 4192)
3254 
(1804 to 8660)
1030 
(558 to 2844)
474 
(240 to 1708)
FS51ORIG[I] 3262 
(1654 to 15366)
998 
(530 to 4066)
432 
(220 to 1108)
320 
(206 to 538)
212 
(132 to 348)
186 
(112 to 312)
1452 
(856 to 2902)
518 
(314 to 1096)
284 
(158 to 698)
1610 
(966 to 3106)
566 
(346 to 1138)
306 
(176 to 684)
FS52BETA[I] – – – 318
(206 to 534)
210
(132 to 348)
182
(112 to 314)
1470
(910 to 2526)
502
(310 to 902)
260
(148 to 534)
1888
(1156 to 4114)
696
(434 to 1416)
398
(240 to 808)
INRIA[D] – – – 270 
(180 to 464)
168 
(112 to 282)
142 
(92 to 240)
448 
(294 to 788)
258 
(168 to 432)
210 
(134 to 350)
306 
(222 to 458)
158 
(116 to 228)
122 
(88 to 186)
IOWA[I] 1542
(918 to 3004)
550 
(332 to 1080)
302 
(174 to 652)
464 
(302 to 812)
256 
(162 to 444)
206 
(124 to 360)
1584 
(938 to 3234)
556 
(340 to 1072)
300 
(178 to 648)
1142 
(826 to 1706)
484 
(350 to 760)
320 
(218 to 536)
MAYO[I] 1064 
(636 to 2008)
484 
(284 to 998)
340 
(188 to 736)
320 
(212 to 544)
202 
(132 to 340)
172 
(110 to 294)
458 
(354 to 656)
190 
(146 to 268)
124 
(86 to 186)
722 
(522 to 1064)
316 
(230 to 484)
216 
(142 to 356)
MAYO_BSI[D] 1214 
(742 to 2152)
432 
(274 to 800)
238 
(140 to 536)
340 
(218 to 610)
200 
(126 to 354)
164 
(100 to 296)
– – – – – –
MAYO_TBM[D] 708 
(466 to 1352)
338 
(204 to 716)
246 
(140 to 572)
288 
(188 to 490)
182 
(116 to 300)
156 
(98 to 268)
1398 
(746 to 4024)
582 
(306 to 1852)
378 
(194 to 1250)
1326 
(776 to 2844)
562 
(324 to 1354)
372 
(194 to 956)
MNI[I] 1294 
(772 to 2508)
458 
(286 to 834)
250 
(144 to 510)
312 
(202 to 520)
204 
(130 to 338)
176 
(110 to 300)
3258 
(1742 to 
7646)
1016 
(552 to 2498)
456 
(226 to 1194)
3844 
(2094 to 9896)
1272 
(706 to 3348)
628 
(334 to 1818)
UCL[I] 1804 
(1072 to 3480)
568 
(336 to 1132)
258 
(138 to 630)
354 
(232 to 594)
226 
(146 to 384)
196 
(124 to 340)
2918 
(1698 to 
6760)
908 
(530 to 2114)
404 
(214 to 1108)
3254 
(1636 to 7906)
1066 
(546 to 2610)
518 
(262 to 1290)
UCL_BSI[D] 452 
(294 to 880)
242 
(154 to 422)
188 
(114 to 336)
314 
(200 to 536)
216 
(136 to 360)
190 
(118 to 320)
1046 
(640 to 1824)
470 
(290 to 794)
326 
(194 to 564)
1144 
(748 to 1858)
476 
(320 to 762)
308 
(204 to 524)
UPENN[I] – – – – – – 1474 
(894 to 3106)
524 
(312 to 1170)
286 
(154 to 710)
3800 
(1666 to 15752)
1520 
(628 to 7018)
948 
(358 to 4986)
UPENN_DBM[D] – – – – – – 1684 
(998 to 3640)
592 
(348 to 1392)
320 
(170 to 824)
4398 
(1906 to 18456)
1692 
(708 to 7592)
1014
(374 to 5300)
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Fig. 5. Sample region delineation fromMIRIAD atrophy challenge subject 220A. Each column represents a submission and the rows show a different region outlined in green (from top to
bottom): whole brain, lateral ventricles, and hippocampi. In one case, INRIA, only a probabilistic mask was used, and this is shown with colour overlays.
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This was replicated by Holland et al. (2012) who used the KN-BSI data
uploaded to ADNI from UCL and obtained a two year sample size esti-
mate of 180 (129 to 276) for two years; in this cohort, the estimate
was 188 (114 to 336). For ventricles, the sample size estimate is 190
(118 to 320) for MIRIAD and 257 (177 to 417) from ADNI. The slightly
larger differences may be that Holland and colleagues did not have ac-
cess to the KN-BSI results in ADNI for the ventricles. Holland et al.
study also provided sample size estimates for FreeSurfer using the
ADNI data, though this might have been performed on a different soft-
ware version compared to the challenge. For whole brain, the estimate
for ADNI was 696 (393 to 1693) and for MIRIAD 432 (220 to 1108)
and 646 (276 to 7832) for the two submissions. For ventricles, the
values were 255 (174 to 427) for ADNI and 186 (112 and 312) and
182 (112 to 314) for the challenge. More formal comparisons of these
sample size estimates across data cohorts will be of interest and the
focus of future work.
The least consistent structure across all assessments was the hippo-
campi, with required sample sizes sometimes varying as much as ten-
fold between techniques. This variability between techniques is likely
due to the numerous deﬁnitions of the hippocampus used in segmenta-
tion protocols. Fig. 5 provides example delineations of the same image
from all the challenge techniques for a single subject. This discrepancy
has lead to an EADC initiative (Boccardi et al., 2011; Frisoni et al.,
2015) to create a uniﬁed hippocampal segmentation protocol based
on previous protocols from the literature and additional input from nu-
merous experts during iterations of the universal protocol. Despite this
variability, the results are in-line with a previous study using manual
delineations of hippocampi in 36 patients and 20 controls from this
dataset (Barnes et al., 2008), which reported 12 m rates of atrophy
to be in the order of 4.5%/year for patients, and 0.3%/year for controls.
A future comparison of hippocampal atrophy techniques based on a
consistent ROI deﬁnition across participants could be of considerable
interest.
As the hippocampus, and the temporal lobe in general, is one of the
areasmost likely to be affected byMRI acquisition artefacts (susceptibil-
ity, ﬂow, motion), this could be another source of error in segmentation
on other atrophy measurements. Since the hippocampus is such asmall structure (roughly 0.2 to 0.4% of total brain volume), and
images are discrete in nature, any mis-classiﬁcation has a much
greater effect on the results, with methods that compute change
based on volumetric differences likely more affected than those based
on direct change.
The techniques providing the sample sizes using hippocampal atro-
phy were similar in magnitude to those for ventricular atrophy. In gen-
eral, compared to sample sizes reported using the ADNI dataset,
hippocampal sample sizes are larger in MIRIAD. Using the UCL BSI tech-
nique in the hippocampi, sample size estimates were 490 (290 to 794)
in MIRIAD and 135 (79 to 301) for ADNI (Leung et al., 2010a); and for
FreeSurfer 284 (158 to 698) for MIRIAD and 217 (150 to 355) in ADNI
(Holland et al., 2012). These higher sample sizes could be due to coarser
resolution of the T1weighted images inMIRIAD,moremodern scanners
and coils available inmany of theADNI sites or underlying differences in
the AD population between the two cohorts.
For all analysis regarding required sample sizes, it is important to con-
sider uncertainty in these estimates, as the point estimate may provide a
very low sample size, but the resulting conﬁdence intervals may be very
wide. It is also important to directly compare sample sizes using signiﬁ-
cance tests, not rely on inferences made from the extent to which conﬁ-
dence intervals overlap. We use the non-parametric bootstrap to
construct conﬁdence intervals and make direct comparisons between
sample sizes.
Most methods showed no clear signs of bias as indicated by their
mean same day and two week atrophy rates. However there were a
couple of exceptions (Baumip, INRIA, and Iowa). It is possible that
these methodologies exhibit a systematic bias that is consistent
across all groups, hence not affecting the sample size estimation, al-
though this is not guaranteed. Measures of reliability and reproduc-
ibility are important factors to consider in addition to the sample size
estimates when determining which imaging biomarker is most ap-
propriate for use as an endpoint in a clinical trial. In the BAUMIP sub-
mission, the non-zero rates were almost certainly caused by the
constraint that was placed in the pipeline where follow-up scans
that were greater than the identiﬁed baseline (or in the case of the
ventricles, less than the identiﬁed baseline) were not allowed to
have a change of greater than 0. This constraint was based on the
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cerebri that can affect the volume of brain parenchyma would be de-
tected and excluded from any clinical study of AD. Whilst it is plausi-
ble to assume elderly subjects, whether they are healthy or have
dementia, will not demonstrate brain growth, there are many
sources of measurement error that might cause this effect within
an MRI scan; and as demonstrated in previous therapeutic studies,
brain swelling, perhaps reﬂecting therapy-related inﬂammation,
can occur. The variability of these short interval atrophy rates also
provides some insight on the repeatability of these measures. In
this case, the spread of these errors was greater for the ventricle
rather than the brain. As mentioned before, this could be due to the
non-speciﬁc nature of ventricle change. The hippocampus again
had the largest spread of errors. In another test–retest variability
study, 5 subjects were recruited at 8 participating sites with differ-
ent 3 T scanners, and two T1 scans were acquired 7 to 60 days
apart. Morphometric results were computed using the cross-
sectional and longitudinal FreeSurfer stream (Jovicich et al., 2014).
The mean test–retest variability across all 8 sites was 1.8 ± 0.4 for hip-
pocampus and 2.3 ± 0.4% for lateral ventricles. These test–retest vari-
ability values are similar to many of the participant's results in this
challenge.
For techniques that produced so-called direct measurements of
change, symmetry and transitivity differences were assessed. In
the brain and ventricle, these differences were small. In the hippo-
campus, particularly within the controls, these differences were
very large when compared to the overall measured change. The
UPENN_DBM method has median values that are elevated in the
right hippocampi for AD compared to other groups, though the
95% conﬁdence intervals still span across 0, indicating that there is
likely no bias present. The larger values are likely due to there
being very little actual change in the structure, thus it is a measure-
ment with low signal and high noise. Fig. 6 provides plots of the hip-
pocampi using the summed 6-month measurements on the vertical
axis and the change using only the baseline and 12month in the hor-
izontal axis. For all the different methods, the controls are tightly
centred around 0, so it is very possible that very small differences
will represent a large percentage of the average amount of change.
Additional measures of transitivity, including different normaliza-
tion strategies, should be explored.
In all but two of the 12 cases listed in Table 3, themethod producing
the lowest sample size was a “direct” technique measuring change be-
tween two scan pairs. In the two caseswhere an indirect technique pro-
duced the lowest sample size (Mayo), there was no signiﬁcant
difference with a direct method (INRIA). Direct measures of change
are desirable because they combine information from the two imagesFig. 6. Transitivity plots comparing 12month atrophymeasures in the hippocampi. Blue points
methods. A dashed line at y = x is present to indicate where a perfectly transitive measure wotogether and measure the difference between these images, which
should reduce the variability caused by segmentation errors. However,
it is worth noting that many methods that are classiﬁed as indirect in
this study actually incorporate information from all/other time-points
within a subject to be more longitudinally consistent, which should re-
duce within subject variance, and produce lower sample size estimates
than if data from fewer time-points was available. When incorporating
information from multiple time-points to reduce variability, it is
important to design these methods such that they ensure as little
bias and loss of sensitivity as possible. Methods that incorporate
longitudinal smoothing as a constraint have the potential of reducing
sensitivity of actual changes between two individual time points.
Since these indirect measures that incorporate longitudinal consis-
tency typically improve with more data and the sample sizes are
based upon using all of the data available for a subject, it is possible
that our predictions for sample sizes for clinical trials involving just
one pre- and one post-randomization measures are all underestimates
of what would be required. However this does not invalidate using
the approach that we have adopted for making comparisons between
techniques.
Our analysis does have some other limitations. Due to space con-
straints we do not consider the effects of missing data on required
sample sizes. Missing data can arise through subject drop out or by
images not being deemed suitable due to poor quality. Its effects
can be allowed for using a pattern-mixture approach as advocated
by Dawson and Lagakos (1991 and 1993) and described by Frost
et al. (2008). We also here consider only simple trial designs with
two visits, one at baseline and the other at the end of follow-up, ig-
noring the potential advantages of including interim visits in the de-
sign. Both of these issues are explored using the original MIRIAD data
in the work of Schott et al. (2006). The method of blinding imple-
mented in this challenge could be considered an obstacle in terms
of getting the largest effective size. In terms of a tradeoff between
bias and variability, we erred more on the side of removing potential
sources of positive bias by blinding the participants to disease group,
as well as the time between scans. As a result, it wasmore difﬁcult for
the participants to identify potential outliers and take corrective ac-
tion. Many of these methods have been developed and validated
using the ADNI datasets, acquired at both 1.5 T and 3 T, whereas all
of the data from the MIRIAD atrophy challenge was acquired on a
1.5 T scanner using different parameters than those used in ADNI.
Whilst most methods show good agreement whether the data was
acquired on 1.5 T or 3 T scanners, such that they are often pooled
for analysis in clinical trials, it is possible that the difference in proto-
cols resulted in slightly different behaviour than that seen in ADNI.
Finally, this data represents a snapshot of the state of the artindicate controls and red points AD patients. Different point glyphs are used to distinguish
uld be located.
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time when the MIRIAD atrophy challenge was completed. However,
since that time, many of the participants have techniques that have
continued to evolve and improve.
Conclusion
In this paper, we provide a systematic framework utilizing a com-
mon data-set allowing a variety of techniques designed to measure
change in brain, ventricles and hippocampi to be evaluated and com-
pared. Despite the differences in techniques, challenge participants
from around the world produced consistent and repeatable measures
of change, particularly for the ventricle and the brain. Hippocampal
measures are more variable, likely due to the differing deﬁnitions of
the structure. We demonstrate that, in general, direct measures of
change are associated with smaller variances than indirect measures;
and that the statistical model previously designed to analyse multiple
time-pointwhole brain atrophy is also able tomodel rates of hippocam-
pal atrophy and ventricular expansion accurately, and thus to provide
estimates of within and between subject variability in rates of change.
Our results suggest that sample size estimates based on ventricular ex-
pansion rates aremore consistent than those fromwhole brain atrophy,
and both are markedly more stable than those derived from hippocam-
pal atrophy measures. By providing comparisons between techniques
based on sample size, our aim is not to determine which techniques
should or should not be used for any given trial – noting that factors
other than sample size alone need to be taken into accountwhen choos-
ing an imaging technique – but to provide the clinical trials community
with robust sample size estimates for trials based on contemporary
techniques; and in the absence of a ground truth, to provide the
imaging community with a means of comparison. To this end the
MIRIAD dataset – in both a blinded (challenge) and unblinded (ordered)
form – will remain publicly available at http://www.ucl.ac.uk/drc/
research/miriad-scan-database for the community to continue to evaluate
their methods. The statistical analysis as it was performed in the challenge
will also be available so that new submissions can be evaluated
using the same methods.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2015.07.087.
Acknowledgments
The public release of the dataset used for the challenge is made avail-
able through the support of the UK Alzheimer's Society. The original data
collection was funded through an unrestricted educational grant from
GlaxoSmithKline and funding from the UK Alzheimer's Society (to Dr
Schott) and theMedical Research Council (to Professor Fox). The Demen-
tia Research Centre is an Alzheimer's Research UK Co-ordinating Centre
and has also received equipment funded by the Alzheimer's Research
UK, Brain Research Trust and The Wolfson Foundation. This work was
supported by the NIHR UCL/UCLH Biomedical Research Centre and
NIHR Queen Square Dementia Biomedical Research Unit. The BAUMIP
Team isﬁnancially supportedby the Scientiﬁc andTechnological Research
Council of Turkey under the grants BIDEB 2215 (L.O. Iheme) and Career
Grant 111E083 (D. Unay and M. Kandemir). The INRIA team was funded
by the European Research Council through the ERC Advanced Grant
MedYMA, and the French ANR “programme blanc” number ANR-09-
BLAN-0332. The MNI group (N. Guizard, Dr. Fonov and Dr. Collins) was
funded by the MS Society of Canada (BioMed PhD studentship, 691)
and the Canadian Institutes of Health Research (MOP-111169 & 84360).
The UCL team receives support from the UCL Leonard Wolfson Experi-
mental Neurology Centre (PR/ylr/18575) and EPSRC (EP/H046410/1)
and the Alzheimer's Disease Neuroimaging Initiative. The UPENN team
would like to acknowledge funding from the NIH grant R01 AG037376.
S.O. receives funding from the EPSRC (EP/H046410/1, EP/J020990/1, EP/
K005278), the MRC (MR/J01107X/1), the EU-FP7 project VPH-DARE@IT(FP7-ICT-2011-9-601055), the NIHR Queen Square Dementia Biomedical
ResearchUnit and theNIHRUCL/UCLHBiomedical Research Centre (NIHR
BRC UCLH/UCL High Impact Initiative—BW.mn.BRC10269).References
Ashburner, J., Friston, K.J., 2005. Uniﬁed segmentation. Neuroimage 26, 839–851.
Avants, B.B., Epstein, C.L., Grossman, M., Gee, J.C., 2008. Symmetric diffeomorphic image
registrationwith cross-correlation: evaluating automated labeling of elderly and neu-
rodegenerative brain. Med. Image Anal. 12, 26–41.
Barnes, J., Scahill, R.I., Frost, C., Schott, J.M., Rossor, M.N., Fox, N.C., 2008. Increased hippo-
campal atrophy rates in AD over 6 months using serial MR imaging. Neurobiol. Aging
29, 1199–1203.
Benzinger, T.L.S., Blazey, T., Jack, C.R., Koeppe, R. a, Su, Y., Xiong, C., Raichle, M.E., Snyder, A.Z.,
Ances, B.M., Bateman, R.J., Cairns, N.J., Fagan, A.M., Goate, A., Marcus, D.S., Aisen, P.S.,
Christensen, J.J., Ercole, L., Hornbeck, R.C., Farrar, A.M., Aldea, P., Jasielec, M.S., Owen,
C.J., Xie, X., Mayeux, R., Brickman, A., McDade, E., Klunk, W., Mathis, C. a, Ringman, J.,
Thompson, P.M., Ghetti, B., Saykin, A.J., Sperling, R. a, Johnson, K. a, Salloway, S.,
Correia, S., Schoﬁeld, P.R., Masters, C.L., Rowe, C., Villemagne, V.L., Martins, R., Ourselin,
S., Rossor, M.N., Fox, N.C., Cash, D.M., Weiner, M.W., Holtzman, D.M., Buckles, V.D.,
Moulder, K., Morris, J.C., 2013. Regional variability of imaging biomarkers in autosomal
dominant Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 110, E4502–E4509.
Bernal-Rusiel, J.L., Greve, D.N., Reuter, M., Fischl, B., Sabuncu, M.R., 2012. Statistical analy-
sis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage
66C, 249–260.
Black, R., Greenberg, B., Ryan, J.M., Posner, H., Seeburger, J., Amatniek, J., Resnick, M.,
Mohs, R., Miller, D.S., Saumier, D., Carrillo, M.C., Stern, Y., 2009. Scales as outcome
measures for Alzheimer's disease. Alzheimers Dement. 5, 324–339.
Boccardi, M., Ganzola, R., Bocchetta, M., Pievani, M., Redolﬁ, A., Bartzokis, G., Camicioli, R.,
Csernansky, J.G., de Leon, M.J., deToledo-Morrell, L., Killiany, R.J., Lehéricy, S., Pantel, J.,
Pruessner, J.C., Soininen, H.,Watson, C., Duchesne, S., Jack, C.R., Frisoni, G.B., 2011. Survey
of protocols for the manual segmentation of the hippocampus: preparatory steps to-
wards a joint EADC-ADNI harmonized protocol. J. Alzheimers Dis. 26 (Suppl. 3), 61–75.
Camara, O., Schnabel, J.a., Ridgway, G.R., Crum,W.R., Douiri, A., Scahill, R.I., Hill, D.L.G., Fox, N.C.,
2008. Accuracy assessment of global and local atrophymeasurement techniques with re-
alistic simulated longitudinal Alzheimer's disease images. Neuroimage 42, 696–709.
Cardoso, M.J., Leung, K., Modat, M., Keihaninejad, S., Cash, D.M., Barnes, J., Fox, N.C.,
Ourselin, S., 2013. STEPS: Similarity and Truth Estimation for Propagated Segmenta-
tions and its application to hippocampal segmentation and brain parcelation. Med.
Image Anal. 17, 671–684.
Collins, D.L., Evans, A.C., 1997. Animal: validation and applications of nonlinear
registration-based segmentation. Int. J. Pattern Recognit. Artif. Intell. 11,
1271–1294.
Coupé, P., Manjón, J.V., Fonov, V., Pruessner, J., Robles, M., Collins, D.L., 2011. Patch-based
segmentation using expert priors: application to hippocampus and ventricle segmen-
tation. Neuroimage 54, 940–954.
Dale, A.M., Fischl, B., Sereno, M.I., 1999. Cortical surface-based analysis I: segmentation
and surface reconstruction. Neuroimage 9, 179–194.
Dawson, J.D., Lagakos, S.W., 1991. Analyzing laboratory marker changes in AIDS clinical
trials. Journal of AIDS 4, 667–676.
Dawson, J.D., Lagakos, S.W., 1993. Size and power of two-sample tests of repeated mea-
sures data. Biometrics 49, 1022–1032.
Diggle, P., Heagerty, P., Liang, K.-Y., Zeger, S., 2002. Analysis of Longitudinal Data. 2nd ed.
OUP Oxford.
Efron, B., Tibshirani, R.J., 1994. An Introduction to the Bootstrap. CRC press.
Eskildsen, S.F., Coupé, P., Fonov, V., Manjón, J.V., Leung, K.K., Guizard, N., Wassef, S.N.,
Ostergaard, L.R., Collins, D.L., 2012. BEaST: Brain extraction based on nonlocal seg-
mentation technique. NeuroImage 59 (3), 2362–2373.
Fischl, B., 2012. FreeSurfer. Neuroimage 62, 774–781.
Fischl, B., Salat, D.H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., Van Der Kouwe, A.,
Killiany, R., Kennedy, D., Klaveness, S., Montillo, A., Makris, N., Rosen, B., Dale, A.M.,
2002. Whole brain segmentation: automated labeling of neuroanatomical structures
in the human brain. Neuron 33, 341–355.
Fonov, V.S., Coupé, P., Styner, M., Collins, D.L., 2012. Automatic lateral ventricle segmenta-
tion in infant populationwith high risk of autism. AnnualMeeting of the Organisation
for Human Brain Mapping. Beijing, China.
Fox, N.C., Ridgway, G.R., Schott, J.M., 2011. Algorithms, atrophy and Alzheimer's disease:
cautionary tales for clinical trials. Neuroimage 57, 15–18.
Freeborough, P.A., Fox, N.C., 1997. The boundary shift integral: an accurate and robust
measure of cerebral volume changes from registered repeat MRI. IEEE Trans. Med.
Imaging 16, 623–629.
Frison, L., Pocock, S.J., 1992. Repeated measures in clinical trials: analysis using mean
summary statistics and its implications for design. Stat. Med. 11, 1685–1704.
Frisoni, G.B., Jack, C.R., Bocchetta, M., Bauer, C., Frederiksen, K.S., Liu, Y., Preboske, G.,
Swihart, T., Blair, M., Cavedo, E., Grothe, M.J., Lanfredi, M., Martinez, O., Nishikawa,
M., Portegies, M., Stoub, T., Ward, C., Apostolova, L.G., Ganzola, R., Wolf, D., Barkhof,
F., Bartzokis, G., DeCarli, C., Csernansky, J.G., DeToledo-Morrell, L., Geerlings, M.I.,
Kaye, J., Killiany, R.J., Lehéricy, S., Matsuda, H., O'Brien, J., Silbert, L.C., Scheltens, P.,
Soininen, H., Teipel, S., Waldemar, G., Fellgiebel, A., Barnes, J., Firbank, M., Gerritsen,
L., Henneman, W., Malykhin, N., Pruessner, J.C., Wang, L., Watson, C., Wolf, H.,
DeLeon, M., Pantel, J., Ferrari, C., Bosco, P., Pasqualetti, P., Duchesne, S., Duvernoy,
H., Boccardi, M., 2015. The EADC-ADNI Harmonized Protocol formanual hippocampal
segmentation onmagnetic resonance: Evidence of validity. Alzheimer’s & Dementia
11 (2), 111–125.
164 D.M. Cash et al. / NeuroImage 123 (2015) 149–164Frost, C., Kenward, M.G., Fox, N.C., 2004. The analysis of repeated “direct” measures of
change illustrated with an application in longitudinal imaging. Stat. Med. 23,
3275–3286.
Frost, C., Kenward, M.G., Fox, N.C., 2008. Optimizing the design of clinical trials where the
outcome is a rate. Can estimating a baseline rate in a run-in period increase efﬁcien-
cy? Stat. Med. 27, 3717–3731.
Gunter, J.L., Shiung, M.M., Manduca, A., Jack, C.R., 2003. Methodological considerations for
measuring rates of brain atrophy. J. Magn. Reson. Imaging 18, 16–24.
Holland, D., Dale, A.M., 2011. Nonlinear registration of longitudinal images and measure-
ment of change in regions of interest. Med. Image Anal. 15, 489–497.
Holland, D., McEvoy, L.K., Dale, A.M., 2012. Unbiased comparison of sample size esti-
mates from longitudinal structural measures in ADNI. Hum. Brain Mapp. 33,
2586–2602.
Hsu, Y.Y., Schuff, N., Du, A.T., Mark, K., Zhu, X., Hardin, D., Weiner, M.W., 2002. Comparison
of automated and manual MRI volumetry of hippocampus in normal aging and de-
mentia. J. Magn. Reson. Imaging 16, 305–310.
Hua, X., Hibar, D.P., Ching, C.R.K., Boyle, C.P., Rajagopalan, P., Gutman, B.A., Leow, A.D.,
Toga, A.W., Jack, C.R., Harvey, D., Weiner, M.W., Thompson, P.M., 2013. Unbiased
tensor-based morphometry: improved robustness and sample size estimates for
Alzheimer's disease clinical trials. Neuroimage 66, 648–661.
Jack, C.R., Shiung, M.M., Gunter, J.L., O'Brien, P.C., Weigand, S.D., Knopman, D.S., Boeve,
B.F., Ivnik, R.J., Smith, G.E., Cha, R.H., Tangalos, E.G., Petersen, R.C., 2004. Comparison
of different MRI brain atrophy rate measures with clinical disease progression in
AD. Neurology 62, 591–600.
Jack, C.R., Knopman, D.S., Jagust, W.J., Petersen, R.C., Weiner, M.W., Aisen, P.S., Shaw, L.M.,
Vemuri, P., Wiste, H.J., Weigand, S.D., Lesnick, T.G., Pankratz, V.S., Donohue, M.C.,
Trojanowski, J.Q., 2013. Tracking pathophysiological processes in Alzheimer's disease:
an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207–216.
Jenkinson, M., Smith, S., 2001. A global optimisation method for robust afﬁne registration
of brain images. Med. Image Anal. 5, 143–156.
Jovicich, J., Marizzoni, M., Bosch, B., Bartrés-Faz, D., Arnold, J., Benninghoff, J., Wiltfang, J.,
Roccatagliata, L., Picco, A., Nobili, F., Blin, O., Bombois, S., Lopes, R., Bordet, R.,
Chanoine, V., Ranjeva, J.-P., Didic, M., Gros-Dagnac, H., Payoux, P., Zoccatelli, G.,
Alessandrini, F., Beltramello, A., Bargalló, N., Ferretti, A., Caulo, M., Aiello, M.,
Ragucci, M., Soricelli, A., Salvadori, N., Tarducci, R., Floridi, P., Tsolaki, M.,
Constantinidis, M., Drevelegas, A., Rossini, P.M., Marra, C., Otto, J., Reiss-
Zimmermann, M., Hoffmann, K.-T., Galluzzi, S., Frisoni, G.B., 2014. Multisite longitudi-
nal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy el-
derly subjects. Neuroimage 101, 390–403.
Kempton, M.J., Underwood, T.S. a, Brunton, S., Stylios, F., Schmechtig, A., Ettinger, U.,
Smith, M.S., Lovestone, S., Crum, W.R., Frangou, S., Williams, S.C.R., Simmons, A.,
2011. A comprehensive testing protocol for MRI neuroanatomical segmentation tech-
niques: evaluation of a novel lateral ventricle segmentation method. Neuroimage 58,
1051–1059.
Leung, K.K., Barnes, J., Ridgway, G.R., Bartlett, J.W., Clarkson, M.J., Macdonald, K., Schuff, N.,
Fox, N.C., Ourselin, S., 2010a. Automated cross-sectional and longitudinal hippocam-
pal volume measurement in mild cognitive impairment and Alzheimer's disease.
Neuroimage 51, 1345–1359.
Leung, K.K., Clarkson, M.J., Bartlett, J.W., Clegg, S., Jack, C.R., Weiner, M.W., Fox, N.C.,
Ourselin, S., 2010b. Robust atrophy rate measurement in Alzheimer's disease using
multi-site serial MRI: tissue-speciﬁc intensity normalization and parameter selection.
Neuroimage 50, 516–523.
Leung, K.K., Barnes, J., Modat, M., Ridgway, G.R., Bartlett, J.W., Fox, N.C., Ourselin, S., 2011a.
Brain MAPS: an automated, accurate and robust brain extraction technique using a
template library. Neuroimage 55, 1091–1108.
Leung, K.K., Ridgway, G.R., Ourselin, S., Fox, N.C., 2011b. Consistent multi-time-point brain
atrophy estimation from the boundary shift integral. Neuroimage 59, 3995–4005.
Lorenzi, M., Ayache, N., Frisoni, G.B., Pennec, X., 2013. LCC-Demons: a robust and accurate
symmetric diffeomorphic registration algorithm. Neuroimage 81, 470–483.
Lorenzi, M., Ayache, N., Pennec, X., 2015. Regional ﬂux analysis for discovering and quan-
tifying anatomical changes: an application to the brain morphometry in Alzheimer's
disease. Neuroimage 115, 224–234.Magnotta, V. a, Harris, G., Andreasen, N.C., O'Leary, D.S., Yuh, W.T.C., Heckel, D., 2002.
Structural MR image processing using the BRAINS2 toolbox. Comput. Med. Imaging
Graph. 26, 251–264.
Malone, I.B., Cash, D., Ridgway, G.R., MacManus, D.G., Ourselin, S., Fox, N.C., Schott, J.M.,
2013. MIRIAD—public release of a multiple time point Alzheimer's MR imaging
dataset. Neuroimage 70, 33–36.
Marcus, D.S., Olsen, T.R., Ramaratnam, M., Buckner, R.L., 2007. The extensible neuroimag-
ing archive toolkit and sharing neuroimaging data. Neuroinformatics 5, 11–34.
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984. Clinical
diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group* under
the auspices of Department of Health and Human Services Task Force on Alzheimer's
Disease. Neurology 34, 939.
Modat, M., Ridgway, G.R., Taylor, Z.a., Lehmann, M., Barnes, J., Hawkes, D.J., Fox, N.C.,
Ourselin, S., 2010. Fast free-form deformation using graphics processing units.
Comput. Methods Programs Biomed. 98, 278–284.
Ourselin, S., Roche, A., Subsol, G., Pennec, X., Ayache, N., 2001. Reconstructing a 3D struc-
ture from serial histological sections. Image Vis. Comput. 19, 25–31.
Patenaude, B., Smith, S.M., Kennedy, D.N., Jenkinson, M., 2011. A Bayesian model of shape
and appearance for subcortical brain segmentation. Neuroimage 56, 907–922.
Pierson, R., Johnson, H., Harris, G., Keefe, H., Paulsen, J.S., Andreasen, N.C., Magnotta, V. a,
2011. Fully automated analysis using BRAINS: AutoWorkup. Neuroimage 54,
328–336.
Reuter, M., Rosas, H.D., Fischl, B., 2010. Highly accurate inverse consistent registration: a
robust approach. Neuroimage 53, 1181–1196.
Reuter, M., Schmansky, N.J., Rosas, H.D., Fischl, B., 2012. Within-subject template estima-
tion for unbiased longitudinal image analysis. Neuroimage 61, 1402–1418.
Schott, J.M., Frost, C., Whitwell, J.L., Macmanus, D.G., Boyes, R.G., Rossor, M.N., Fox, N.C.,
2006. Combining short interval MRI in Alzheimer's disease: implications for thera-
peutic trials. J. Neurol. 253, 1147–1153.
Schott, J.M., Bartlett, J.W., Fox, N.C., Barnes, J., 2010. Increased brain atrophy rates in cog-
nitively normal older adults with low cerebrospinal ﬂuid Aβ1–42. Ann. Neurol. 68,
825–834.
Sled, J.G., Zijdenbos, a P., Evans, a C., 1998. A nonparametric method for automatic correc-
tion of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 17, 87–97.
Smith, S.M., Rao, A., De Stefano, N., Jenkinson, M., Schott, J.M., Matthews, P.M., Fox, N.C.,
2007. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease:
cross-validation of BSI, SIENA and SIENAX. Neuroimage 36, 1200–1206.
Tustison, N.J., Avants, B.B., Cook, P. a, Zheng, Y., Egan, A., Yushkevich, P. a, Gee, J.C., 2010.
N4ITK: improved N3 bias correction. IEEE Trans. Med. Imaging 29, 1310–1320.
Van Leemput, K., Maes, F., Vandermeulen, D., Suetens, P., 1999. Automated model-based
tissue classiﬁcation of MR images of the brain. IEEE Trans. Med. Imaging 18, 897–908.
Verbeke, G., Molenberghs, G., 2000. Linear Mixed Models for Longitudinal Data. Springer
Series in Statistics. Springer New York, New York, NY.
Vercauteren, T., Pennec, X., Perchant, A., Ayache, N., 2008. Symmetric Log-Domain
Diffeomorphic Registration : A Demons-Based Approach. Medical Image Computing
and Computer-Assisted Intervention (MICCAI2008), Part I, Volume 5241 of Lecture
Notes in Computer Science, pp. 754–761.
Villemagne, V.L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. a, Salvado, O., Szoeke, C.,
Macaulay, S.L., Martins, R., Maruff, P., Ames, D., Rowe, C.C., Masters, C.L., 2013. Amy-
loid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's
disease: a prospective cohort study. Lancet Neurol. 12, 357–367.
Wang, L., Yushkevich, P., Ourselin, S. (Eds.), 2012. MICCAI 2012 Workshop on Novel Im-
aging Biomarkers for Alzheimer's Disease and Related Disorders (NIBAD12).
Wyman, B.T., Harvey, D.J., Crawford, K., Bernstein, M. a, Carmichael, O., Cole, P.E., Crane,
P.K., Decarli, C., Fox, N.C., Gunter, J.L., Hill, D., Killiany, R.J., Pachai, C., Schwarz, A.J.,
Schuff, N., Senjem, M.L., Suhy, J., Thompson, P.M., Weiner, M., Jack, C.R., 2012. Stan-
dardization of analysis sets for reporting results from ADNI MRI data. Alzheimers
Dement. 1–6.
Yushkevich, P.a., Avants, B.B., Das, S.R., Pluta, J., Altinay, M., Craige, C., 2010. Bias in estima-
tion of hippocampal atrophy using deformation-based morphometry arises from
asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage
50, 434–445.
